Management of anemia induced by triple therapy in patients with chronic hepatitis C: Challenges, opportunities and recommendations

Journal of Hepatology

Volumn 59, Issue 6, 2013, Pages 1323-1330

  Romero Gómez, Manuel ^a   Berenguer, Marina ^b   Molina, Esther ^c   Calleja, José Luis ^d  

^a HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

^c HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^d HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

Author keywords

Anemia; Boceprevir; Epoietin; Hepatitis C virus; Pegylated interferon; Protease inhibitor; Ribavirin; Telaprevir

Indexed keywords

BOCEPREVIR; FERRITIN; HEMOGLOBIN; INOSINE TRIPHOSPHATE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT ERYTHROPOIETIN; RIBAVIRIN; TELAPREVIR; TRANSFERRIN;

ANEMIA; CONVULSION; DRUG DOSE REDUCTION; DRUG INDUCED HEADACHE; ERYTHROCYTE CONCENTRATE; ERYTHROCYTE TRANSFUSION; GENOTYPE; HEMOGLOBIN DETERMINATION; HEMOLYTIC ANEMIA; HEPATITIS C; HUMAN; HYPERTENSION; INJECTION SITE PAIN; PRIORITY JOURNAL; PURE RED CELL ANEMIA; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM;

ANEMIA; BMI; BOCEPREVIR; BODY MASS INDEX; EPO; EPOIETIN; ERYTHROPOIETIN; GENOME-WIDE ASSOCIATION STUDY; GWAS; HCV; HEPATITIS C VIRUS; INOSINE TRIPHOSPHATE PYROPHOSPHATASE; ITPA; PEGYLATED INTERFERON; PROTEASE INHIBITOR; RIBAVIRIN; SINGLE NUCLEOTIDE POLYMORPHISMS; SNP; SRFT; TELAPREVIR; TRANSFERRIN SOLUBLE RECEPTOR;

ANEMIA; DRUG THERAPY, COMBINATION; ERYTHROCYTE TRANSFUSION; ERYTHROPOIETIN; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LIVER TRANSPLANTATION; POLYETHYLENE GLYCOLS; PROTEASE INHIBITORS; RECOMBINANT PROTEINS; RIBAVIRIN;

EID: 84888011097     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2013.07.014     Document Type: Review

References (34)

1. EASL Clinical practice guidelines: management of hepatitis C virus infection J Hepatol 55 2011 245 264
2. M.G. Ghany, D.B. Strader, D.L. Thomas, and L.B. Seef Diagnosis, management and treatment of hepatitis C: an update Hepatology 49 2009 1335 1374
3. B. Bacon, S.C. Gordon, E. Lawitz, P. Marcellin, J.M. Vierling, and S. Zeuzem Boceprevir for previously treated chronic HCV genotype 1 infection N Engl J Med 364 2011 1207 1217
4. F. Poordad, J. McCone, B.R. Bacon, S. Bruno, M.P. Manns, and M.S. Sulkowski Boceprevir for untreated chronic HCV genotype 1 infection N Engl J Med 364 2011 1195 1206
5. K.E. Sherman, S.L. Flamm, N.H. Afdhal, D.R. Nelson, M.S. Sulkowski, and G.T. Everson Response-guided telaprevir combination treatment or hepatitis C virus infection N Engl J Med 364 2011 1014 1024
6. I. Jacobson, J. McHutchison, G. Dusheiko, A.M. Di Bisceglie, K.R. Reddy, and N.H. Bzowej Telaprevir for previously untreated chronic hepatitis C virus infection N Engl J Med 364 2011 2405 2416
7. S. Zeuzem, P. Andreone, S. Pol, E. Lawitz, M. Diago, and S. Roberts Telaprevir for retreatment of HCV infection N Engl J Med 364 2011 2417 2428
8. C. Hezode, C. Dorival, F. Zoulim, D. Larrey, S. Pol, and P. Cacoud ANRS CO20 CUPIC study group. Safety of telaprevir or boceprevir in combination with peginterferon alfa/ribavirin, in cirrhotic non-responders. Week 16 analysis of the French early access program in real life setting Hepatology 56 2012 217A 218A
9. N. Reau, S.J. Hadziyannis, D. Messinger, M.W. Fried, and D.M. Jensen Early predictors of anemia in patients with hepatitis C genotype 1 treated with peginterferon-alfa-2a (40KD) plus ribavirin Am J Gastroenterol 103 2008 1981 1988
10. J. Fellay, A.J. Thompson, D. Ge, C.E. Gumbs, T.J. Urban, and K.V. Shianna ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C Nature 464 2010 405 408
11. S. Zeuzem, R. De Masi, A. Baldini, B. Coate, D. Luo, and J. Mrus Factors predictive of anemia development in treatment-experienced patients receiving telaprevir (T; TVR) plus peginterferon/ribavirin (PR) in the REALIZE trial Hepatology 56 2012 564A 565A
12. F.F. Poordad, E.J. Lawitz, K.R. Reddy, D.R. Nelson, D. Strader, and D.L. Thomas A randomized trial comparing ribavirin dose reduction vs. erythropoietin for anemia management in previously untreated patients with chronic hepatitis C receiving boceprevir plus peginterferon/ribavirin J Hepatol 56 2012 S559
13. M.S. Sulkowski, F. Poordad, M.P. Manns, J.P. Bronowicki, K.R. Reddy, and S.A. Harrison Anemia during treatment with peginterferon alfa-2b/ribavirin and boceprevir: analysis from the SPRINT-2 trial Hepatology 57 2013 974 984
14. P.Y. Kwo, E.J. Lawitz, J. McCone, E.R. Schiff, J.M. Vierling, and D. Pound Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial Lancet 376 2010 705 716
15. A. Aghemo, E. Degasperi, and M. Colombo Directly acting antivirals for the treatment of chronic hepatitis C: unresolved topics from registration trials Dig Liver Dis 45 2013 1 7
16. A.J. Thompson, J. Fellay, K. Patel, H.L. Tillmann, S. Naggie, and D. Ge Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction Gastroenterology 139 2010 1181 1189
17. M. Rau, F. Stickel, S. Russmann, C.N. Manser, P.P. Becker, and M. Weisskopf Impact of genetic SLC28 transporter and ITPA variants on ribavirin serum level, hemoglobin drop and therapeutic response in patients with HCV infection J Hepatol 58 2013 669 675
18. F. Suzuki, Y. Suzuki, N. Akuta, H. Sezaki, M. Hirakawa, and Y. Kawamura Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir Hepatology 53 2011 415 421
19. K. Chayama, C.N. Hayes, H. Abe, D. Miki, H. Ochi, and Y. Karino IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C J Infect Dis 204 2011 84 93
20. M.S. Sulkowski, S. Roberts, N. Afdhal, G. Dusheiko, A.M. Di Bisceglie, and K.R. Reddy Ribavirin dose modification in treatment-naïve and previously treated patients who received telaprevir combination treatment: no impact on sustained virologic response in phase 3 J Hepatol 56 2011 S459 S460
21. K.R. Reddy, M.L. Shiffman, T.R. Morgan, S. Zeuzem, S. Hadziyannis, and F.M. Hamzeh Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment Clin Gastroenterol Hepatol 5 2007 124 129
22. M.S. Sulkowski, M.L. Shiffman, N.H. Afdhal, K.R. Reddy, J. McCone, and W.M. Lee Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate Gastroenterology 139 2010 1602 1611
23. E. Lawitz, S. Zeuzem, L.M. Nyberg, D.R. Nelson, L. Rossaro, and L.A. Balart Boceprevir (BOC) combined with peginterferon alfa-2b/ribavirin (P/RBV) in treatment-naïve chronic HCV genotype 1 patients with compensated cirrhosis: sustained virologic response (SVR) and safety subanalyses from the Anemia Management Study Hepatology 56 2012 216A
24. P. Glue The clinical pharmacology of ribavirin Semin Liv Dis 19 1999 17 24
25. J.D. Rizzo, M. Brouwers, P. Hurley, J. Seidenfeld, M.O. Arcasoy, and J.L. Spivak American society of hematology/American society of clinical oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer Blood 116 2010 4045 4059
26. M. Sherman, L. Cohen, M.A. Cooper, M. Elkashab, V. Feinman, and D. Fletcher Clinical recommendations for the use of recombinant human erythropoietin in patients with hepatitis C virus being treated with ribavirin Can J Gastroenterol 20 2006 479 485
27. M. Berenguer Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin J Hepatol 49 2008 274 287
28. C.S. Wang, H.H. Ko, E.M. Yoshida, C.A. Marra, and K. Richardson Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis Am J Transplant 6 2006 1586 1599
29. K.S. Gurusamy, E. Tsochatzis, E. Xirouchakis, A.K. Burroughs, and B.R. Davidson Antiviral therapy for recurrent liver graft infection with hepatitis C virus Cochrane Database Syst Rev 20 2010 CD006803
30. S. Saab, M.K. Oh, A.B. Ibrahim, F. Durazo, S. Han, and H. Yersiz Anemia in liver transplant recipients undergoing antiviral treatment for recurrent hepatitis C Liver Transpl 13 2007 1032 1038
31. M. Giusto, M. Rodriguez, L. Navarro, A. Rubin, V. Aguilera, and F. San-Juan Anemia is not predictive of sustained viral response in HCV-liver transplant recipients treated with peg-interferon and ribavirin Liver Transpl 17 2011 1318 1327
32. A. Coilly, B. Roche, J. Dumortier, V. Botta-Fridlund, V. Leroy, and G.P. Pageaux Efficacy and safety of protease inhibitors to treat Hepatitis C recurrence after liver transplantation: a first multicentric experience Hepatology 56 2012 9A
33. M. Colombo, I. Fernández, D. Abdurakhmanov, P.A. Ferreira, S. Strasser, and P. Urbanek Management and outcomes of anemia in the international telaprevir early access program, for patients with hepatitis C genotype 1 infection J Hepatol 58 2013 S329 806P
34. P.S. Belperio, E.W. Hwang, I.C. Thomas, L.A. Mole, R.C. Cheung, and L.I. Backus Early virologic responses and hematologic safety of direct-acting antiviral therapies in veterans with chronic hepatitis C Clin Gastroenterol Hepatol 11 2013 1021 1027